FDA Inspection 1014639 — Guilin Sanjin Pharmaceutical Co Ltd
The FDA completed an inspection of Guilin Sanjin Pharmaceutical Co Ltd on May 19, 2017 in Guilin. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- May 19, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Guilin (China)